Introduction: There are two commercially available tests for measurement of serum free light chains (sFLC) in multiple myeloma (MM) patients - Freelite and N Latex FLC. The aim of this study was to perform an assessment and direct comparison of the usefulness of the methods in routine clinical practice.

Methods: 40 refractory/relapsed MM patients underwent routine disease activity assessment studies, along with sFLC analysis using both assays. Correlation and concordance between the tests and sensitivity of studied methods of sFLC assessment were established. Special attention was focused on sFLC results in patients finally evaluated after completing the treatment.

Results: A weak correlation for the measurement of both κ [Passing-Bablok slope (PB) = 0.7681] and λ chains [(PB) = 1.542] was found. Using Bland-Altman plots, a bias of 0.0467 (κ) and -0.2133 (λ) between the measurements was documented. The concordance coefficient equaled 0.87 for κ, 0.62 for λ and 0.52 for κ/λ ratio. Ten patients had an abnormal Freelite assay κ/λ ratio and normal N Latex FLC κ/λ ratio. Three of these patients had negative serum protein electrophoresis results and fulfilled diagnostic criteria of stringent complete remission (sCR) according to N Latex FLC (but not according to Freelite). When the κ/λ ratio obtained by both methods was compared to patients' serum/urine protein electrophoresis and immunofixation results, sensitivity of Freelite and N Latex FLC was established to be 62.5% and 41%, respectively.

Conclusions: There was no strong correlation or concordance between the two assays, and the sensitivity in terms of sFLC detection was different. This may cause problems when diagnosis of sCR is considered.

Download full-text PDF

Source
http://dx.doi.org/10.5604/17322693.1229346DOI Listing

Publication Analysis

Top Keywords

latex flc
16
κ/λ ratio
16
serum free
8
free light
8
light chains
8
multiple myeloma
8
freelite latex
8
correlation concordance
8
protein electrophoresis
8
patients
6

Similar Publications

With the introduction of newer platforms for sFLC estimation, more comparative attempts are required to establish an assay-specific reference range, that can be used in the day-to-day clinical management of the patients, as the revised criteria for the diagnosis of myeloma recommend the use of involved Free light chain (FLC)/uninvolved FLC ratio as myeloma defining event, solely relying on Freelite assay. This was an observational study that included 101 patients, 55 (54.5%) with M-protein (myeloma), and 46 (45.

View Article and Find Full Text PDF

Multiple myeloma (MM) is a disease, that at times poses diagnostic and monitoring challenges. Over the last decades laboratory methods have been expanded with serum free light chain (FLC) analysis. Alerted by two index cases with clinical impact due to failure of the FLC analysis to indicate a disease progression, we aimed to identify any clinical consequences due to known differences between FLC analysis methods.

View Article and Find Full Text PDF

Background: A substantial number of patients with multiple myeloma (MM) who have bone destruction are initially admitted into the orthopedic service at the hospital. However, routine laboratory testing usually fails to identify these patients, thus delaying optimal therapy. Therefore, there is a clear medical need for early diagnosis of MM in these patients.

View Article and Find Full Text PDF
Article Synopsis
  • The study compares two assays for measuring free light chains (FLC) in serum—Freelite with the SPAplus analyzer and N Latex FLC with the Atellica CH 930 analyzer—focusing on their diagnostic effectiveness for plasma cell disorders, particularly multiple myeloma.
  • A total of 322 serum samples were collected from 193 patients, and while the N Latex FLC assay showed good precision and reliability for routine use, significant discrepancies (up to 170% bias) arose in high-concentration samples, particularly for lambda light chains.
  • The findings highlight the importance of consistency in assay selection for monitoring disease status in multiple myeloma, as changing platforms can lead
View Article and Find Full Text PDF
Article Synopsis
  • The study investigated the effectiveness of the new Nipro ELISIO-17HX medium-cut-off dialyzer compared to the Baxter Theranova 400 in patients undergoing hemodialysis, focusing on the removal of middle molecules.
  • Results indicated that while the ELISIO-HX had slightly lower reduction ratios for certain proteins, it caused significantly less albumin loss and had a better overall removal score than Theranova.
  • The findings suggest that the ELISIO-HX dialyzer could offer a beneficial option for hemodialysis, potentially improving patient outcomes.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!